- Home
- MOV vs SLS Comparison
MOV vs SLS Comparison
Compare MOV & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOV | SLS |
|---|---|---|
| Founded | 1961 | 2012 |
| Country | United States | United States |
| Employees | 1386 | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 854.9M | 924.5M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | MOV | SLS |
|---|---|---|
| Price | $37.61 | $14.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $31.50 | $10.00 |
| AVG Volume (30 Days) | 298.8K | ★ 9.8M |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $0.67 | $110.98 |
| P/E Ratio | $25.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.78 | $1.39 |
| 52 Week High | $39.85 | $15.88 |
Technical Indicators
Market Signals| Indicator | MOV | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 73.51 |
| Support Level | $35.92 | $3.91 |
| Resistance Level | $39.20 | N/A |
| Average True Range (ATR) | 1.16 | 1.26 |
| MACD | -0.39 | 0.63 |
| Stochastic Oscillator | 31.50 | 89.04 |
Price Performance
Historical ComparisonAbout MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.